Introduction
The weak interactions between crown ethers and neutral organic molecules are of chemical and biological interest. The study of such interactions may lead to the design of specific host molecules for small neutral biologically active compounds, as well as to a better understanding of secondary interactions that occur at biological receptors or enzyme pockets. These weak interactions may be of importance in stereoselective recognition by receptors and substrates. Although a number of structures of 18-crown-6 ethers with charged species have been described, only the neutral complexes with dimethyl acetylenedicarboxylate (1:1) (Goldberg, 1975) , dimethyl sulfone (1:1) (Weber & Vfgtle, 1980) , urea (1:5) (Harkema, Van Hummel, Daasvatn & Reinhoudt, 1981) and benzenesulfonamide (1:2) (Knochel, Kopf, Oehler & Rudolph, 1978) have been reported. We would like to describe the A 1:2 HOST-GUEST COMPLEX C12H2406.2CvHTNO2 structure of the 1:2 complex formed between 1,4,7,10,13,16-hexaoxacyclooctadecane and phenyl carbamate.
Structure determination and refinement A crystal of dimensions 0.38 x 0.25 x 0.20 mm was selected for all X-ray measurements. Intensity data were collected on a Syntex P2~ diffractometer system by the 0:20 scanning technique using a variable scan speed, Cu Ka radiation (2 = 1.54178/k) and a graphite monochromator. Room-temperature lattice parameters were refined by a least-squares procedure utilizing 15 reflections whose angles were measured by a centering routine associated with the diffractometer. The unit cell was found to be monoclinic, and systematic absences were consistent with space group P21/c. A periodically monitored reflection showed no significant change in intensity. Of the 2314 independent reflections measured (20 < 130 °) 1518 had intensities greater than 33(I). Lorentz and polarization corrections were applied, but no absorption corrections were made.
The direct-methods program MULTAN 78 (Main, Lessinger, Woolfson, Germain & Declercq, 1978 )was used to calculate phases for the 350 LEI values greater than 1.45. The phase set with the highest combined figure of merit was selected, and the E map calculated with these phases revealed the positions of all nonhydrogen atoms. After several cycles of refinement difference Fourier maps yielded the coordinates of all hydrogen atoms. After anisotropic refinement of the heavy-atom positions, the data were corrected for extinction through use of the equation I F*I ---k l Fcl (1 + 2r*lFcl2~) -1/4 (Larson, 1970) . ~5 is a dimensionless constant for each reflection and r* was refined to a value of 5 (1) (6)O(7) 66.3 (2) -66.6 C(5)C(6)O (7)C(8) 179.4 (2) 180.0 C(6)O(7)C(8)C (9) 178-0 (2) -72.5 O(7)C(8)C (9) Table 4 , the conformation of the 18-crown-6 ether is not identical to that in the 1:2 benzenesulfonamide complex which is also described as having D3d symmetry (Knochel, Kopf, Oehler & Rudolph, 1978) although significant deviations from this symmetry are apparent. The C-O and C-C distances average 1.414 (4) Phenyl carbamate molecules are located about the center of symmetry on both sides of the ether moiety. The NH 2 groups are oriented toward the cavity and are hydrogen bonded to two oxygen atoms unrelated by symmetry. The conformation of the 18-crown-6 ether is not the same as that in the benzenesulfonamide complex, where hydrogen bonds involve oxygen atoms related by the center of symmetry. The distances and Table 5 . Hydrogen-bond distances (/k) angles describing the hydrogen bonding in the phenyl carbamate complex are presented in Table 5 . There are no intermolecular contacts, other than the hydrogen bonding, which are shorter than 3.6 A.
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Introduction
Since it was first synthesized in 1915 (Bayer & Co., 1915) and used clinically (Unna, 1916) , dithranol 0567-7408/82/041248-04501.00
(1) has remained the most widely prescribed preparation used exclusively for the treatment of psoriasis (Weigand & Everett, 1967) . Its mode of action involves its ability to oxidize readily within the epidermal tissues which, by enzymatic inhibition, results in a slowing down of cellular proliferation (Fisher & Maibach, 1975) , with subsequent clinical clearance.
(1)
Spectroscopic (Avdovitch & Neville, 1980) and crystallographic (Ahmed, 1980) examination of dithranol has recently shown that it exists as the keto tautomer, 1,8-dihydroxy-9(10H)anthrone (1). When (1) was dissolved in acetone, Segal, Katz & van Duuren (1971) were able to obtain a dimeric species to
